Mapping the human genome has made it possible to quickly and economically refine a patient’s cancer risk through an analysis of inherited mutations. Our inherited cancer test panel is one of the industry’s largest.
Screening for hereditary cancers gives patients—especially those with a family history of cancer—relevant information about their cancer risk, and helps providers make more informed decisions and develop an appropriate preventative or treatment plan.
Our carrier screening allows providers to determine if prospective parents carry a genetic mutation that could cause a serious inherited disorder in their baby, such as cystic fibrosis, sickle cell and Tay-Sachs disease.
Newborn genetic screening identifies genetic disorders in infants. Early intervention to treat these disorders can help eliminate or reduce symptoms that might otherwise cause a lifetime of disability.
Studies have shown that incorporating genetic factors into the prescribing process can help improve efficacy, reduce adverse effects and help avoid drug-drug interactions.
Our pharmacogenetic tests help healthcare providers target treatment and medications to a patient’s genetics by analyzing the genes that produce the specific drug targets, or enzymes that metabolize a medication or are associated with immune response.